KR20230165761A - 전립선암의 진단 방법 - Google Patents

전립선암의 진단 방법 Download PDF

Info

Publication number
KR20230165761A
KR20230165761A KR1020237032903A KR20237032903A KR20230165761A KR 20230165761 A KR20230165761 A KR 20230165761A KR 1020237032903 A KR1020237032903 A KR 1020237032903A KR 20237032903 A KR20237032903 A KR 20237032903A KR 20230165761 A KR20230165761 A KR 20230165761A
Authority
KR
South Korea
Prior art keywords
radioligand
psma
imaging agent
pet
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237032903A
Other languages
English (en)
Korean (ko)
Inventor
아나 카타파우
엘리자벳 파레라 피엘라
베일리 헤
을로지 크파메간
Original Assignee
어드밴스드 엑셀러레이터 어플리케이션즈
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어드밴스드 엑셀러레이터 어플리케이션즈, 노파르티스 아게 filed Critical 어드밴스드 엑셀러레이터 어플리케이션즈
Publication of KR20230165761A publication Critical patent/KR20230165761A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020237032903A 2021-04-02 2022-04-01 전립선암의 진단 방법 Pending KR20230165761A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305432 2021-04-02
EP21305432.3 2021-04-02
PCT/EP2022/058754 WO2022207906A1 (en) 2021-04-02 2022-04-01 Diagnostic methods of prostate cancer

Publications (1)

Publication Number Publication Date
KR20230165761A true KR20230165761A (ko) 2023-12-05

Family

ID=75588163

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237032903A Pending KR20230165761A (ko) 2021-04-02 2022-04-01 전립선암의 진단 방법

Country Status (9)

Country Link
US (1) US20240181092A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313175A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514293A (cg-RX-API-DMAC7.html)
KR (1) KR20230165761A (cg-RX-API-DMAC7.html)
CN (1) CN117120100A (cg-RX-API-DMAC7.html)
CA (1) CA3215723A1 (cg-RX-API-DMAC7.html)
IL (1) IL307381A (cg-RX-API-DMAC7.html)
TW (1) TW202304531A (cg-RX-API-DMAC7.html)
WO (1) WO2022207906A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
CN120897762A (zh) * 2023-04-12 2025-11-04 康奈尔大学 用于治疗癌症的放射治疗缀合物
WO2026027442A1 (en) 2024-08-01 2026-02-05 Novartis Ag Synthesis of a precursor of radiopharmaceutical products

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173630A1 (en) * 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Formulation of radiopharmaceuticals containing multiple acidic groups
WO2013173583A1 (en) 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
SMT202300035T1 (it) * 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
KR20240027896A (ko) * 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법

Also Published As

Publication number Publication date
TW202304531A (zh) 2023-02-01
CN117120100A (zh) 2023-11-24
JP2024514293A (ja) 2024-04-01
WO2022207906A1 (en) 2022-10-06
IL307381A (en) 2023-11-01
CA3215723A1 (en) 2022-10-06
EP4313175A1 (en) 2024-02-07
US20240181092A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
Lohrmann et al. Retooling a blood-based biomarker: phase I assessment of the high-affinity CA19-9 antibody HuMab-5B1 for immuno-PET imaging of pancreatic cancer
EP4313175A1 (en) Diagnostic methods of prostate cancer
Bhattacharyya et al. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas
Granov et al. Positron emission tomography
Natarajan et al. Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model
US20250025584A1 (en) Radiopharmaceutical treatment methods and use
Ha et al. Dosimetric analysis of a phase I study of PSMA-targeting radiopharmaceutical therapy with [177Lu] ludotadipep in patients with metastatic castration-resistant prostate cancer
KR20250044688A (ko) 표적화된 분자 영상화를 위한 구리의 방사성 제약 조성물
RU2702294C1 (ru) Способ радионуклидной диагностики операбельного рака молочной железы с гиперэкспрессией Her2/neu
US20250269073A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
RU2700109C1 (ru) Способ радионуклидной диагностики вторичной отечно-инфильтративной формы рака молочной железы с гиперэкспрессией Her2/neu с использованием рекомбинантных адресных молекул DARPin9_29
Ruangma et al. PSMA for PET imaging of prostate cancer
AU2018381046B2 (en) Radiolabeled progastrin in cancer diagnosis
Baum et al. Third theranostics world congress on gallium-68 and PRRT: abstracts
US20240042067A1 (en) [177lu] lutetium-psma i&t composition, kit, method of making, and method of using thereof
US20250032651A1 (en) [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
Young Imaging and therapeutic radiotracers for prostate cancer
Lucignani Non-standard PET radionuclides: time to get ready for new clinical PET strategies
CA3085067C (en) Radiolabeled progastrin in cancer diagnosis
Bailey Advancing targeting radiopharmaceuticals for theranostic applications
Omweri Development of Radiochemistry of 52Mn for PET Imaging Applications
Hoang Development of Antibody-Based Theranostic Agents for Delta-Like Ligand 3-Expressing Neuroendocrine Neoplasms
Elison et al. ANZSNM ASM 2021 POSTER PRESENTATIONS
Lam Translation and Development of Molecular Imaging Probes for Detecting Response of Breast Cancer to Trastuzumab
Abusalem Development of PSMA-Targeted Radiopharmaceuticals for Routine Clinical Applications

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230925

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20240313

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250401

Comment text: Request for Examination of Application